Ⓐ
PeptiBrief
Phase 1 trial· 2009

Phase I and pharmacokinetic study of angiotensin-1-7, an endogenous antiangiogenic hormone

Petty WJ|Miller AA|McCoy TP|Gallagher PE|Tallant EA|Torti FM

Clinical Cancer Research

DOI
10.1158/1078-0432.ccr-09-1957
PubMed
19920106
Evidence level
moderate
Verification
verified

Summary

A phase 1 trial evaluated subcutaneous angiotensin-1-7 in patients with advanced solid tumours.

Limitations

Small dose-escalation study|Advanced cancer population|No control group|Not evidence for general cardiovascular or wellness use

Linked peptides

Important PeptiBrief is an educational information platform. It does not diagnose, prescribe, sell peptides, recommend dosing, encourage self-experimentation or replace qualified medical care. Published scientific evidence is kept separate from community observations and uncertainty.